Regenerative medicine company Orthocell
(ASX:OCC) have seen the first four patients successfully complete participation in the CelGro® nerve regeneration clinical trial.
Following surgery with CelGro®, patients have regained muscle function and/or sensation of affected limbs and have returned to work, sport and activities of daily living.
The patients had previously suffered traumatic peripheral nerve injuries following motor vehicle, sporting and work-related incidents, resulting in complete paralysis, or impaired use of the upper limb.
Shares in Orthocell
(ASX:OCC) closed flat at 11.5 cents yesterday.
